No Data
Taiko Pharmaceutical 9-Mos Net Y714.00M Vs Loss Y562.00M
Taiko Pharmaceutical: Consolidated financial results report for the 3rd quarter of the fiscal year ending 2024/12 (FY2024)
Taiko Pharmaceutical: Summary of financial results for the 3rd quarter of the fiscal year ending 2024/12 [Japanese GAAP] (consolidated)
Morinaga Milk, mcdonald's, Toyo Suisan, Eisai (8th) (1429-5463)
※Please note that the above calendar is tentative and subject to change based on the company's convenience. --------------------------------------- November 8th (Fri) <1429> Japan Aqua <1435> RoboHome <143A> Ishin <1450> Tanaka Construction Industry <1451> KHC <1518> Mitsui Matsushima HD <151A> Dai <167A> Ryo
Daiko Pharmaceuticals Research Memo (3): Change of policy to a two-factory production system for the pharmaceutical business. "Cleverin" targets students preparing for examinations.
■ DaiKo Yakuhin <4574> Topics 1. Pharmaceutical business: Strengthening supply capacity, smooth progress in price increases. The external environment of the pharmaceutical business is favorable. The increase in opportunities to go out and the demand from inbound visitors are tailwinds, and the domestic anti-diarrhea market is surpassing pre-COVID-19 levels. The stable supply from the company has been key to expanding market share, and efforts have been made to strengthen the shift production system at the Suita and Oguni factories, as well as to launch the packaging line for 'Seirogan Sugar Coated A' at the Kyoto factory.
Daiko Pharmaceutical Research Memo (2): Increased revenue and profit for the fiscal year ending December 2024. Revised upward forecast for operating and ordinary profit.
For the fiscal year ending December 2024, we expect revenue of 6,800 million yen (an increase of 11.1% compared to the previous year), operating profit of 550 million yen (a loss of 1,005 million yen in the previous year), ordinary profit of 590 million yen (a loss of 1,248 million yen in the previous year), and net income attributable to the parent company shareholders of 550 million yen (a loss of 3,611 million yen in the previous year).
No Data
No Data